● TIER 1 — FDA-approved / recognizedGRADE AGLP-1 / incretins & amylin
Orforglipron
Oral non-peptide GLP-1 RA. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Approved Apr 1 2026: Foundayo (chronic weight management, adults)
Compounding (503A/503B)
Not compoundable (no bulks listing).
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
Small-molecule GLP-1R agonist, once-daily oral without food restriction.
Human evidence · 1
Trial Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Reference only. This page summarizes publicly available regulatory and research information about Orforglipron. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.